Publications from OUS - Computational Oncology (Sveen)

70 publications found

Publications 2026

  1. Kranjec C, Eilertsen IA, Nunes L, Moosavi SH, Berg KCG, Eknæs M, Hektoen M, Niederdorfer B, Lind GE, Skotheim RI, Sveen A, Lothe RA (2026)
    Common gene mutations in 103 authenticated colorectal cancer cell lines
    Oncogenesis, 15 (1), 8
    DOI 10.1038/s41389-026-00599-0, PubMed 41593049
  2. Kryeziu K, Klokkerud SK, Totland MZ, Moosavi SH, Reims HM, Bergsland CH, Eilertsen IA, Smeby J, Lassen K, Lundesgaard KK, Syversveen T, Brændengen M, Nesbakken A, Guren TK, Yaqub S, Sveen A, Lothe RA (2026)
    Patient-derived organoids from metastatic colorectal cancer mirror tumor heterogeneity and predict patient survival and drug sensitivity
    Cell Rep Med, 7 (6), 102840
    DOI 10.1016/j.xcrm.2026.102840, PubMed 42208542
  3. Morken S, Langer SW, Hjortland GO, Sundlöv A, Hofsli E, Ladekarl M, Tabaksblat E, Vestermark LW, Svensson J, Knigge U, Nunes L, Glimelius B, Pfeiffer P, Aasebø K, Assmus J, Vassella E, Lothe IMB, Couvelard A, Perren A, Knappskog S, Sorbye H (2026)
    Molecular-clinical characteristics and treatment outcomes in 163 metastatic colorectal neuroendocrine carcinomas with a comparison to colorectal adenocarcinomas
    Int J Cancer, 158 (12), 3217-3231
    DOI 10.1002/ijc.70367, PubMed 41642024
  4. Nunes L, Nesbakken A, Lothe RA, Sveen A (2026)
    Temporal Trends in Cancer Mortality Among People Younger Than 50 Years in Norway
    JAMA Netw Open, 9 (8), e2629437
    DOI 10.1001/jamanetworkopen.2026.29437, PubMed 42599710
  5. Panagopoulos I, Stranger A, Sveen A, Jareid M, Kidd SG, Bischof K, Taskén K, Dørum A, Davidson B, Lothe RA, Skotheim RI, Johannessen B (2026)
    Fusion gene heterogeneity and kinase enrichment in high-grade serous carcinomas
    Neoplasia, 79, 101332
    DOI 10.1016/j.neo.2026.101332, PubMed 42349107
  6. Sveen A, Bergsland CH, Niederdorfer B, Berstad AE, Bjerkehagen B, Boye K, Guren TK, Lothe RA (2026)
    Pembrolizumab in advanced malignant peripheral nerve sheath tumors: a single-arm phase 2 trial
    NPJ Precis Oncol, 10 (1)
    DOI 10.1038/s41698-026-01303-6, PubMed 41760889
  7. Sveen A, Stenersen JM, Asenso TQ, Klokkerud SK, Kranjec C, Eilertsen IA, Johannessen B, Leithe E, Kryeziu K, Zucknick M, Lothe RA (2026)
    Exceptional treatment responses and molecular markers among 103 colorectal cancer cell lines
    Mol Biomed, 7 (1)
    DOI 10.1186/s43556-026-00551-z, PubMed 42640371
  8. Totland MZ, Rasmussen NL, Elster VCW, Arnesen KI, Bergmann DG, Bergill I, Stenersen JM, Larsen M, Moe JJ, Basing S, Sørensen V, Aasen T, Leithe E (2026)
    Regulation of ubiquitination and degradation of the gap junction channel protein Connexin43 involves the concerted action of multiple members of the NEDD4 family of E3 ubiquitin ligases
    Cancer Lett, 659, 218796 (in press)
    DOI 10.1016/j.canlet.2026.218796, PubMed 42641867

Publications 2025

  1. Gudiño V, Bartolomé-Casado R, Salas A (2025)
    Single-cell omics in inflammatory bowel disease: recent insights and future clinical applications
    Gut, 74 (8), 1335-1345
    DOI 10.1136/gutjnl-2024-334165, PubMed 39904604
  2. Moosavi SH, Kryeziu K, Eilertsen IA, Nunes L, Hektoen M, Niederdorfer B, Reims HM, Syversveen T, Grut H, Dueland S, Line PD, Lothe RA, Sveen A (2025)
    Molecular prognostic factors for liver transplantation of unresectable metastatic colorectal cancer
    Br J Surg, 112 (4)
    DOI 10.1093/bjs/znaf072, PubMed 40235343
  3. Osterlund E, Hammarström K, Nunes L, Mathot L, Mezheyeuski A, Sjöblom T, Glimelius B (2025)
    Primary tumour location, molecular alterations, treatments, and outcome in a population-based metastatic colorectal cancer cohort
    BJC Rep, 3 (1), 38
    DOI 10.1038/s44276-025-00156-z, PubMed 40437037
  4. Osterlund E, Ristimäki A, Nunes L, Kytölä S, Aho S, Heervä E, Uutela A, Lehtomäki K, Stedt H, Halonen P, Kontiainen J, Muhonen T, Kallio R, Sundström J, Ålgars A, Ristamäki R, Nieminen L, Sorbye H, Pfeiffer P, Salminen T, Nordin A, Lamminmäki A, Mäkinen MJ, Sjöblom T, Isoniemi H, Glimelius B, Osterlund P (2025)
    KRAS and NRAS mutations in Nordic population-based and real-world metastatic colorectal cancer cohorts
    BJC Rep, 3 (1), 72
    DOI 10.1038/s44276-025-00188-5, PubMed 41120702
  5. Shi Z, Ren H, Lin C, Li F, Wu M, Yang F, Luo T, Nunes L, Isaksson A, Hammarström K, Zhu T, Zhu S, Zhong Y, Ljuslinder I, Uhlén M, Palmqvist R, Glimelius B, Wu K, Sjöblom T, Zhong H (2025)
    Tissue-resident microbiota impacts colorectal cancer progression and prognosis
    Nat Commun, 17 (1), 346
    DOI 10.1038/s41467-025-67047-2, PubMed 41354681

Publications 2024

  1. Langerud J, Eilertsen IA, Moosavi SH, Klokkerud SMK, Reims HM, Backe IF, Hektoen M, Sjo OH, Jeanmougin M, Tejpar S, Nesbakken A, Lothe RA, Sveen A (2024)
    Multiregional transcriptomics identifies congruent consensus subtypes with prognostic value beyond tumor heterogeneity of colorectal cancer
    Nat Commun, 15 (1), 4342
    DOI 10.1038/s41467-024-48706-2, PubMed 38773143
  2. Majid U, Bergsland CH, Sveen A, Bruun J, Eilertsen IA, Bækkevold ES, Nesbakken A, Yaqub S, Jahnsen FL, Lothe RA (2024)
    The prognostic effect of tumor-associated macrophages in stage I-III colorectal cancer depends on T cell infiltration
    Cell Oncol (Dordr), 47 (4), 1267-1276
    DOI 10.1007/s13402-024-00926-w, PubMed 38407700
  3. Nunes L, Stenersen JM, Kryeziu K, Sjöblom T, Glimelius B, Lothe RA, Sveen A (2024)
    Co-occurring mutations identify prognostic subgroups of microsatellite stable colorectal cancer
    Mol Cancer, 23 (1), 264
    DOI 10.1186/s12943-024-02173-x, PubMed 39587554
  4. Sveen A, Johannessen B, Klokkerud SM, Kraggerud SM, Meza-Zepeda LA, Bjørnslett M, Bischof K, Myklebost O, Taskén K, Skotheim RI, Dørum A, Davidson B, Lothe RA (2024)
    Evolutionary mode and timing of dissemination of high-grade serous carcinomas
    JCI Insight, 9 (3)
    DOI 10.1172/jci.insight.170423, PubMed 38175731
  5. Totland MZ, Knudsen LM, Rasmussen NL, Omori Y, Sørensen V, Elster VCW, Stenersen JM, Larsen M, Jensen CL, Zickfeldt Lade AA, Bruusgaard E, Basing S, Kryeziu K, Brech A, Aasen T, Lothe RA, Leithe E (2024)
    The E3 ubiquitin ligase ITCH negatively regulates intercellular communication via gap junctions by targeting connexin43 for lysosomal degradation
    Cell Mol Life Sci, 81 (1), 171
    DOI 10.1007/s00018-024-05165-8, PubMed 38597989

Publications 2023

  1. Høland M, Berg KCG, Eilertsen IA, Bjerkehagen B, Kolberg M, Boye K, Lingjærde OC, Guren TK, Mandahl N, van den Berg E, Palmerini E, Smeland S, Picci P, Mertens F, Sveen A, Lothe RA (2023)
    Transcriptomic subtyping of malignant peripheral nerve sheath tumours highlights immune signatures, genomic profiles, patient survival and therapeutic targets
    EBioMedicine, 97, 104829
    DOI 10.1016/j.ebiom.2023.104829, PubMed 37837931

Publications 2022

  1. Bergsland CH, Jeanmougin M, Moosavi SH, Svindland A, Bruun J, Nesbakken A, Sveen A, Lothe RA (2022)
    Spatial analysis and CD25-expression identify regulatory T cells as predictors of a poor prognosis in colorectal cancer
    Mod Pathol, 35 (9), 1236-1246
    DOI 10.1038/s41379-022-01086-8, PubMed 35484226
  2. Kryeziu K, Bergsland CH, Guren TK, Sveen A, Lothe RA (2022)
    Multiplex immunohistochemistry of metastatic colorectal cancer and ex vivo tumor avatars
    Biochim Biophys Acta Rev Cancer, 1877 (1), 188682
    DOI 10.1016/j.bbcan.2022.188682, PubMed 35065193
  3. Strømme JM, Johannessen B, Kidd SG, Bogaard M, Carm KT, Zhang X, Sveen A, Mathelier A, Lothe RA, Axcrona U, Axcrona K, Skotheim RI (2022)
    Expressed prognostic biomarkers for primary prostate cancer independent of multifocality and transcriptome heterogeneity
    Cancer Gene Ther, 29 (8-9), 1276-1284
    DOI 10.1038/s41417-022-00444-7, PubMed 35194199

Publications 2021

  1. Berg KCG, Brunsell TH, Sveen A, Alagaratnam S, Bjørnslett M, Hektoen M, Brudvik KW, Røsok BI, Bjørnbeth BA, Nesbakken A, Lothe RA (2021)
    Genomic and prognostic heterogeneity among RAS/BRAFV600E /TP53 co-mutated resectable colorectal liver metastases
    Mol Oncol, 15 (4), 830-845
    DOI 10.1002/1878-0261.12885, PubMed 33325154
  2. Eide PW, Moosavi SH, Eilertsen IA, Brunsell TH, Langerud J, Berg KCG, Røsok BI, Bjørnbeth BA, Nesbakken A, Lothe RA, Sveen A (2021)
    Metastatic heterogeneity of the consensus molecular subtypes of colorectal cancer
    NPJ Genom Med, 6 (1), 59
    DOI 10.1038/s41525-021-00223-7, PubMed 34262039
  3. Kryeziu K, Moosavi SH, Bergsland CH, Guren MG, Eide PW, Totland MZ, Lassen K, Abildgaard A, Nesbakken A, Sveen A, Lothe RA (2021)
    Increased sensitivity to SMAC mimetic LCL161 identified by longitudinal ex vivo pharmacogenomics of recurrent, KRAS mutated rectal cancer liver metastases
    J Transl Med, 19 (1), 384
    DOI 10.1186/s12967-021-03062-3, PubMed 34496878
  4. Moosavi SH, Eide PW, Eilertsen IA, Brunsell TH, Berg KCG, Røsok BI, Brudvik KW, Bjørnbeth BA, Guren MG, Nesbakken A, Lothe RA, Sveen A (2021)
    De novo transcriptomic subtyping of colorectal cancer liver metastases in the context of tumor heterogeneity
    Genome Med, 13 (1), 143
    DOI 10.1186/s13073-021-00956-1, PubMed 34470666
  5. Slørdahl KS, Klotz D, Olsen JÅ, Skovlund E, Undseth C, Abildgaard HL, Brændengen M, Nesbakken A, Larsen SG, Hanekamp BA, Holmboe L, Tvedt R, Sveen A, Lothe RA, Malinen E, Kaasa S, Guren MG (2021)
    Treatment outcomes and prognostic factors after chemoradiotherapy for anal cancer
    Acta Oncol, 60 (7), 921-930
    DOI 10.1080/0284186X.2021.1918763, PubMed 33966592
  6. Sveen A, Johannessen B, Eilertsen IA, Røsok BI, Gulla M, Eide PW, Bruun J, Kryeziu K, Meza-Zepeda LA, Myklebost O, Bjørnbeth BA, Skotheim RI, Nesbakken A, Lothe RA (2021)
    The expressed mutational landscape of microsatellite stable colorectal cancers
    Genome Med, 13 (1), 142
    DOI 10.1186/s13073-021-00955-2, PubMed 34470667

Publications 2020

  1. Bergsland CH, Bruun J, Guren MG, Svindland A, Bjørnslett M, Smeby J, Hektoen M, Kolberg M, Domingo E, Pellinen T, Tomlinson I, Kerr D, Church DN, Nesbakken A, Sveen A, Lothe RA (2020)
    Prediction of relapse-free survival according to adjuvant chemotherapy and regulator of chromosome condensation 2 (RCC2) expression in colorectal cancer
    ESMO Open, 5 (6), e001040
    DOI 10.1136/esmoopen-2020-001040, PubMed 33219056
  2. Bruun J, Kryeziu K, Eide PW, Moosavi SH, Eilertsen IA, Langerud J, Røsok B, Totland MZ, Brunsell TH, Pellinen T, Saarela J, Bergsland CH, Palmer HG, Brudvik KW, Guren T, Dienstmann R, Guren MG, Nesbakken A, Bjørnbeth BA, Sveen A, Lothe RA (2020)
    Patient-Derived Organoids from Multiple Colorectal Cancer Liver Metastases Reveal Moderate Intra-patient Pharmacotranscriptomic Heterogeneity
    Clin Cancer Res, 26 (15), 4107-4119
    DOI 10.1158/1078-0432.CCR-19-3637, PubMed 32299813
  3. Flatin BTB, Vedeld HM, Pinto R, Langerud J, Lind GE, Lothe RA, Sveen A, Jeanmougin M (2020)
    Multiregional assessment of CIMP in primary colorectal cancers: Phenotype concordance but marker variability
    Int J Cancer, 148 (7), 1652-1657
    DOI 10.1002/ijc.33425, PubMed 33284993
  4. Jeanmougin M, Håvik AB, Cekaite L, Brandal P, Sveen A, Meling TR, Ågesen TH, Scheie D, Heim S, Lothe RA, Lind GE (2020)
    Improved prognostication of glioblastoma beyond molecular subtyping by transcriptional profiling of the tumor microenvironment
    Mol Oncol, 14 (5), 1016-1027
    DOI 10.1002/1878-0261.12668, PubMed 32171051
  5. Smeby J, Kryeziu K, Berg KCG, Eilertsen IA, Eide PW, Johannessen B, Guren MG, Nesbakken A, Bruun J, Lothe RA, Sveen A (2020)
    Molecular correlates of sensitivity to PARP inhibition beyond homologous recombination deficiency in pre-clinical models of colorectal cancer point to wild-type TP53 activity
    EBioMedicine, 59, 102923
    DOI 10.1016/j.ebiom.2020.102923, PubMed 32799124
  6. Wise JF, Nakken S, Steen CB, Vodák D, Trøen G, Johannessen B, Lingjærde OC, Hilden V, Blaker YN, Bai B, Aasheim LB, Pasanen A, Lorenz S, Sveen A, Lothe RA, Myklebost O, Leppä S, Meza-Zepeda LA, Beiske K, Lawrence MS, Hovig E, Myklebust JH, Smeland EB, Holte H (2020)
    Mutational dynamics and immune evasion in diffuse large B-cell lymphoma explored in a relapse-enriched patient series
    Blood Adv, 4 (9), 1859-1866
    DOI 10.1182/bloodadvances.2019001325, PubMed 32374878

Publications 2019

  1. Berg KCG, Sveen A, Høland M, Alagaratnam S, Berg M, Danielsen SA, Nesbakken A, Søreide K, Lothe RA (2019)
    Gene expression profiles of CMS2-epithelial/canonical colorectal cancers are largely driven by DNA copy number gains
    Oncogene, 38 (33), 6109-6122
    DOI 10.1038/s41388-019-0868-5, PubMed 31308487
  2. Brunsell TH, Cengija V, Sveen A, Bjørnbeth BA, Røsok BI, Brudvik KW, Guren MG, Lothe RA, Abildgaard A, Nesbakken A (2019)
    Heterogeneous radiological response to neoadjuvant therapy is associated with poor prognosis after resection of colorectal liver metastases
    Eur J Surg Oncol, 45 (12), 2340-2346
    DOI 10.1016/j.ejso.2019.07.017, PubMed 31350075
  3. Brunsell TH, Sveen A, Bjørnbeth BA, Røsok BI, Danielsen SA, Brudvik KW, Berg KCG, Johannessen B, Cengija V, Abildgaard A, Guren MG, Nesbakken A, Lothe RA (2019)
    High Concordance and Negative Prognostic Impact of RAS/BRAF/PIK3CA Mutations in Multiple Resected Colorectal Liver Metastases
    Clin Colorectal Cancer, 19 (1), e26-e47
    DOI 10.1016/j.clcc.2019.09.003, PubMed 31982351
  4. Dienstmann R, Villacampa G, Sveen A, Mason MJ, Niedzwiecki D, Nesbakken A, Moreno V, Warren RS, Lothe RA, Guinney J (2019)
    Relative contribution of clinicopathological variables, genomic markers, transcriptomic subtyping and microenvironment features for outcome prediction in stage II/III colorectal cancer
    Ann Oncol, 30 (10), 1622-1629
    DOI 10.1093/annonc/mdz287, PubMed 31504112
  5. Eide PW, Eilertsen IA, Sveen A, Lothe RA (2019)
    Long noncoding RNA MIR31HG is a bona fide prognostic marker with colorectal cancer cell-intrinsic properties
    Int J Cancer, 144 (11), 2843-2853
    DOI 10.1002/ijc.31998, PubMed 30447009
  6. Eilertsen IA, Moosavi SH, Strømme JM, Nesbakken A, Johannessen B, Lothe RA, Sveen A (2019)
    Technical differences between sequencing and microarray platforms impact transcriptomic subtyping of colorectal cancer
    Cancer Lett, 469, 246-255
    DOI 10.1016/j.canlet.2019.10.040, PubMed 31678167
  7. Glaire MA, Domingo E, Sveen A, Bruun J, Nesbakken A, Nicholson G, Novelli M, Lawson K, Oukrif D, Kildal W, Danielsen HE, Kerr R, Kerr D, Tomlinson I, Lothe RA, Church DN (2019)
    Tumour-infiltrating CD8+ lymphocytes and colorectal cancer recurrence by tumour and nodal stage
    Br J Cancer, 121 (6), 474-482
    DOI 10.1038/s41416-019-0540-4, PubMed 31388185
  8. Glaire MA, Domingo E, Sveen A, Bruun J, Nesbakken A, Nicholson G, Novelli M, Lawson K, Oukrif D, Kildal W, Danielsen HE, Kerr R, Kerr D, Tomlinson I, Lothe RA, Church DN (2019)
    Correction: Tumour-infiltrating CD8+ lymphocytes and colorectal cancer recurrence by tumour and nodal stage
    Br J Cancer, 121 (9), 807
    DOI 10.1038/s41416-019-0590-7, PubMed 31548598
  9. Kryeziu K, Bruun J, Guren TK, Sveen A, Lothe RA (2019)
    Combination therapies with HSP90 inhibitors against colorectal cancer
    Biochim Biophys Acta Rev Cancer, 1871 (2), 240-247
    DOI 10.1016/j.bbcan.2019.01.002, PubMed 30708039
  10. Smeby J, Sveen A, Bergsland CH, Eilertsen IA, Danielsen SA, Eide PW, Hektoen M, Guren MG, Nesbakken A, Bruun J, Lothe RA (2019)
    Exploratory analyses of consensus molecular subtype-dependent associations of TP53 mutations with immunomodulation and prognosis in colorectal cancer
    ESMO Open, 4 (3), e000523
    DOI 10.1136/esmoopen-2019-000523, PubMed 31321083
  11. Smeby J, Sveen A, Eilertsen IA, Danielsen SA, Hoff AM, Eide PW, Johannessen B, Hektoen M, Skotheim RI, Guren MG, Nesbakken A, Lothe RA (2019)
    Transcriptional and functional consequences of TP53 splice mutations in colorectal cancer
    Oncogenesis, 8 (6), 35
    DOI 10.1038/s41389-019-0141-3, PubMed 31092812
  12. Sveen A, Cremolini C, Dienstmann R (2019)
    Predictive modeling in colorectal cancer: time to move beyond consensus molecular subtypes
    Ann Oncol, 30 (11), 1682-1685
    DOI 10.1093/annonc/mdz412, PubMed 31868904
  13. Sveen A, Kopetz S, Lothe RA (2019)
    Biomarker-guided therapy for colorectal cancer: strength in complexity
    Nat Rev Clin Oncol, 17 (1), 11-32
    DOI 10.1038/s41571-019-0241-1, PubMed 31289352

Publications 2018

  1. Bruun J, Sveen A, Barros R, Eide PW, Eilertsen I, Kolberg M, Pellinen T, David L, Svindland A, Kallioniemi O, Guren MG, Nesbakken A, Almeida R, Lothe RA (2018)
    Prognostic, predictive, and pharmacogenomic assessments of CDX2 refine stratification of colorectal cancer
    Mol Oncol, 12 (9), 1639-1655
    DOI 10.1002/1878-0261.12347, PubMed 29900672
  2. Eilertsen IA, Sveen A, Strømme JM, Skotheim RI, Nesbakken A, Lothe RA (2018)
    Alternative splicing expands the prognostic impact of KRAS in microsatellite stable primary colorectal cancer
    Int J Cancer, 144 (4), 841-847
    DOI 10.1002/ijc.31809, PubMed 30121958
  3. Høland M, Kolberg M, Danielsen SA, Bjerkehagen B, Eilertsen IA, Hektoen M, Mandahl N, van den Berg E, Smeland S, Mertens F, Sundby Hall K, Picci P, Sveen A, Lothe RA (2018)
    Inferior survival for patients with malignant peripheral nerve sheath tumors defined by aberrant TP53
    Mod Pathol, 31 (11), 1694-1707
    DOI 10.1038/s41379-018-0074-y, PubMed 29946184

Publications 2017

  1. Berg KCG, Eide PW, Eilertsen IA, Johannessen B, Bruun J, Danielsen SA, Bjørnslett M, Meza-Zepeda LA, Eknæs M, Lind GE, Myklebost O, Skotheim RI, Sveen A, Lothe RA (2017)
    Multi-omics of 34 colorectal cancer cell lines - a resource for biomedical studies
    Mol Cancer, 16 (1), 116
    DOI 10.1186/s12943-017-0691-y, PubMed 28683746
  2. Dienstmann R, Mason MJ, Sinicrope FA, Phipps AI, Tejpar S, Nesbakken A, Danielsen SA, Sveen A, Buchanan DD, Clendenning M, Rosty C, Bot B, Alberts SR, Milburn Jessup J, Lothe RA, Delorenzi M, Newcomb PA, Sargent D, Guinney J (2017)
    Prediction of overall survival in stage II and III colon cancer beyond TNM system: a retrospective, pooled biomarker study
    Ann Oncol, 28 (5), 1023-1031
    DOI 10.1093/annonc/mdx052, PubMed 28453697
  3. Eide PW, Bruun J, Lothe RA, Sveen A (2017)
    CMScaller: an R package for consensus molecular subtyping of colorectal cancer pre-clinical models
    Sci Rep, 7 (1), 16618
    DOI 10.1038/s41598-017-16747-x, PubMed 29192179
  4. Sveen A, Bruun J, Eide PW, Eilertsen IA, Ramirez L, Murumägi A, Arjama M, Danielsen SA, Kryeziu K, Elez E, Tabernero J, Guinney J, Palmer HG, Nesbakken A, Kallioniemi O, Dienstmann R, Lothe RA (2017)
    Colorectal Cancer Consensus Molecular Subtypes Translated to Preclinical Models Uncover Potentially Targetable Cancer Cell Dependencies
    Clin Cancer Res, 24 (4), 794-806
    DOI 10.1158/1078-0432.CCR-17-1234, PubMed 29242316
  5. Sveen A, Johannessen B, Tengs T, Danielsen SA, Eilertsen IA, Lind GE, Berg KCG, Leithe E, Meza-Zepeda LA, Domingo E, Myklebost O, Kerr D, Tomlinson I, Nesbakken A, Skotheim RI, Lothe RA (2017)
    Multilevel genomics of colorectal cancers with microsatellite instability-clinical impact of JAK1 mutations and consensus molecular subtype 1
    Genome Med, 9 (1), 46
    DOI 10.1186/s13073-017-0434-0, PubMed 28539123

Publications 2016

  1. Moen LV, Ramberg H, Zhao S, Grytli HH, Sveen A, Berge V, Skotheim RI, Taskén KA, Skålhegg BS (2016)
    Observed correlation between the expression levels of catalytic subunit, Cβ2, of cyclic adenosine monophosphate-dependent protein kinase and prostate cancer aggressiveness
    Urol Oncol, 35 (3), 111.e1-111.e8
    DOI 10.1016/j.urolonc.2016.10.002, PubMed 27838142
  2. Ramalho-Carvalho J, Martins JB, Cekaite L, Sveen A, Torres-Ferreira J, Graça I, Costa-Pinheiro P, Eilertsen IA, Antunes L, Oliveira J, Lothe RA, Henrique R, Jerónimo C (2016)
    Epigenetic disruption of miR-130a promotes prostate cancer by targeting SEC23B and DEPDC1
    Cancer Lett, 385, 150-159
    DOI 10.1016/j.canlet.2016.10.028, PubMed 27984115
  3. Sveen A, Løes IM, Alagaratnam S, Nilsen G, Høland M, Lingjærde OC, Sorbye H, Berg KC, Horn A, Angelsen JH, Knappskog S, Lønning PE, Lothe RA (2016)
    Intra-patient Inter-metastatic Genetic Heterogeneity in Colorectal Cancer as a Key Determinant of Survival after Curative Liver Resection
    PLoS Genet, 12 (7), e1006225
    DOI 10.1371/journal.pgen.1006225, PubMed 27472274

Publications 2015

  1. Hoff AM, Johannessen B, Alagaratnam S, Zhao S, Nome T, Løvf M, Bakken AC, Hektoen M, Sveen A, Lothe RA, Skotheim RI (2015)
    Novel RNA variants in colorectal cancers
    Oncotarget, 6 (34), 36587-602
    DOI 10.18632/oncotarget.5500, PubMed 26474385
  2. Johannessen B, Sveen A, Skotheim RI (2015)
    TIN: An R Package for Transcriptome Instability Analysis
    Cancer Inform, 14, 109-12
    DOI 10.4137/CIN.S31363, PubMed 26448683
  3. Sveen A, Kilpinen S, Ruusulehto A, Lothe RA, Skotheim RI (2015)
    Aberrant RNA splicing in cancer; expression changes and driver mutations of splicing factor genes
    Oncogene, 35 (19), 2413-27
    DOI 10.1038/onc.2015.318, PubMed 26300000

Publications 2014

  1. Smebye ML, Sveen A, Haugom L, Davidson B, Tropé CG, Lothe RA, Heim S, Skotheim RI, Micci F (2014)
    Chromosome 19 rearrangements in ovarian carcinomas: zinc finger genes are particularly targeted
    Genes Chromosomes Cancer, 53 (7), 558-67
    DOI 10.1002/gcc.22166, PubMed 24634323
  2. Sveen A, Johannessen B, Teixeira MR, Lothe RA, Skotheim RI (2014)
    Transcriptome instability as a molecular pan-cancer characteristic of carcinomas
    BMC Genomics, 15 (1), 672
    DOI 10.1186/1471-2164-15-672, PubMed 25109687

Publications 2013

  1. Alagaratnam S, Harrison N, Bakken AC, Hoff AM, Jones M, Sveen A, Moore HD, Andrews PW, Lothe RA, Skotheim RI (2013)
    Transforming pluripotency: an exon-level study of malignancy-specific transcripts in human embryonal carcinoma and embryonic stem cells
    Stem Cells Dev, 22 (7), 1136-46
    DOI 10.1089/scd.2012.0369, PubMed 23137282

Publications 2012

  1. Agesen TH, Sveen A, Merok MA, Lind GE, Nesbakken A, Skotheim RI, Lothe RA (2012)
    ColoGuideEx: a robust gene classifier specific for stage II colorectal cancer prognosis
    Gut, 61 (11), 1560-7
    DOI 10.1136/gutjnl-2011-301179, PubMed 22213796
  2. Paulo P, Ribeiro FR, Santos J, Mesquita D, Almeida M, Barros-Silva JD, Itkonen H, Henrique R, Jerónimo C, Sveen A, Mills IG, Skotheim RI, Lothe RA, Teixeira MR (2012)
    Molecular subtyping of primary prostate cancer reveals specific and shared target genes of different ETS rearrangements
    Neoplasia, 14 (7), 600-11
    DOI 10.1593/neo.12600, PubMed 22904677
  3. Sveen A, Bakken AC, Ågesen TH, Lind GE, Nesbakken A, Nordgård O, Brackmann S, Rognum TO, Lothe RA, Skotheim RI (2012)
    The exon-level biomarker SLC39A14 has organ-confined cancer-specificity in colorectal cancer
    Int J Cancer, 131 (6), 1479-85
    DOI 10.1002/ijc.27399, PubMed 22173985
  4. Sveen A, Ågesen TH, Nesbakken A, Meling GI, Rognum TO, Liestøl K, Skotheim RI, Lothe RA (2012)
    ColoGuidePro: a prognostic 7-gene expression signature for stage III colorectal cancer patients
    Clin Cancer Res, 18 (21), 6001-10
    DOI 10.1158/1078-0432.CCR-11-3302, PubMed 22991413

Publications 2011

  1. Danielsen SA, Cekaite L, Ågesen TH, Sveen A, Nesbakken A, Thiis-Evensen E, Skotheim RI, Lind GE, Lothe RA (2011)
    Phospholipase C isozymes are deregulated in colorectal cancer--insights gained from gene set enrichment analysis of the transcriptome
    PLoS One, 6 (9), e24419
    DOI 10.1371/journal.pone.0024419, PubMed 21909432
  2. Sveen A, Agesen TH, Nesbakken A, Rognum TO, Lothe RA, Skotheim RI (2011)
    Transcriptome instability in colorectal cancer identified by exon microarray analyses: Associations with splicing factor expression levels and patient survival
    Genome Med, 3 (5), 32
    DOI 10.1186/gm248, PubMed 21619627

 
Scroll to top